Riociguat - CAS# 625115-55-1 carbazone Smiles: COC1C=CSC=1CNCC[C@]1(CCOC2(C1)CCCC2)C1=CC=CC=N1

Smiles: COC1C=CSC=1CNCC[C@]1(CCOC2(C1)CCCC2)C1=CC=CC=N1

InChi: InChI=1S/C16H18O9/c17-9-3-1-8(5-10(9)18)2-4-13(20)25-12-7-16(24

2016 Jun 21

47-14)32(43)25(7)49-28

Smiles: CC(C)(C)[C@H](NC(=O)[C@@H](NC)C(C)(C)C1C=CC=CC=1)C(=O)N(C)[C@H](/C=C(\C)/C(O)=O)C(C)C

Riociguat - CAS# 625115-55-1 carbazone Smiles: COC1C=CSC=1CNCC[C@]1(CCOC2(C1)CCCC2)C1=CC=CC=N1Riociguat, also known as BAY 63 2521, is a novel drug that is currently in clinical development by Bayer. It is a stimulator of soluble guanylate cyclase (sGC). At the moment Phase III clinical trials investigate the use of riociguat as a new approach to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of a novel class